Detection and Management of Early Glucose Abnormalities in Cystic Fibrosis by Theocharous, Katerina et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
1Chapter
Detection and Management of 
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Abstract
With advances in technology, it is now possible to detect the emergence of glucose 
abnormalities in cystic fibrosis with improved sensitivity, and from a very early age. 
These abnormalities are increasingly recognized as predictors of clinical decline, 
raising the possibility that early intervention may slow or prevent this deterioration. 
In this chapter, we will review the available literature on methods of detecting glu-
cose abnormalities in cystic fibrosis (random and fasting glucose, HbA1c, oral glucose 
tolerance testing, and continuous glucose monitoring), and detail their advantages 
and possible limitations in the interpretation of glycemic data. We will also discuss 
treatment outcomes of early intervention, prior to the diagnosis of diabetes as cur-
rently defined.
Keywords: cystic fibrosis-related diabetes, glucose, insulin, abnormal glucose 
tolerance, indeterminate glycaemia, impaired glucose tolerance, oral glucose tolerance 
test, continuous glucose monitoring
1. Introduction
Historically, cystic fibrosis (CF) caused fatal respiratory failure in early child-
hood [1, 2], but proactive multidisciplinary care has increased life expectancy to 
~44 years [3]. With longer survival, co-morbidities have become more prevalent, 
the commonest being cystic fibrosis-related diabetes (CFRD) [4, 5]. This is associ-
ated with poorer clinical status [6–21], quality of life [22, 23], and life expectancy 
[16, 24, 25] relative to non-diabetic CF patients.
CFRD is distinct from other diabetes mellitus etiologies, including type 1 (T1D) 
and type 2 (T2D) (see Table 1) [4, 5]. It is caused primarily by chronic pancreatitis 
[26–30] with progressive insulin deficiency [9, 11, 31], particularly during first-
phase insulin secretion [8, 9, 11, 19, 32–40]. Variations in peripheral insulin sensi-
tivity also contribute to CFRD [20, 41]; hyperglycemia progressively induces insulin 
resistance via downregulation of glucose transporters [42–44], and insulin sensitiv-
ity decreases with inflammation, use of exogenous glucocorticoids, and puberty 
[45–49]. In CF, the depleted and dysfunctional pancreatic β-cells may be unable to 
compensate for this, producing early intermittent hyperglycemia progressing to 
fasting hyperglycemia [35, 44, 50].
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CFRD is usually preceded by a spectrum of abnormal glucose tolerance (AGT) 
on oral glucose tolerance testing (OGTT), including impaired fasting glucose 
(IFG), indeterminate glucose tolerance (INDET), and impaired glucose tolerance 
(IGT) [4, 51]. There may be ‘waxing and waning’ of glucose tolerance between 
these categories [19, 52–55], probably due to variations in insulin sensitivity [35, 
44]. Nevertheless, large prospective cohort studies report overall deterioration 
in CF patients’ glucose tolerance over life [16, 20, 53, 54, 56]. The date of onset of 
CFRD is considered to be the first time a patient meets diagnostic criteria, even if 
glucose abnormalities subsequently resolve due to improvement in insulin sensitiv-
ity [4]. This is because studies utilizing this definition report correlations between 
CFRD duration, microvascular disease prevalence [57], and mortality [16, 56].
Taken together, these factors explain why CFRD becomes more common with 
age. Prevalence is ~1.5% in CF patients aged <10 years, but ~15% in those aged 
11–17 and ~50% in those aged ≥18 [8, 16, 58]. The American Diabetes Association 
(ADA) recommends annual screening from age 10, using 2-h OGTT [59]. CFRD 
can also be diagnosed using clinical status, random blood glucose, fasting plasma 
Type 1 diabetes Type 2 diabetes CFRD
Prevalence 0.2% 11% 35% (likely underestimated due 
to lack of testing)
Onset Usually acute Insidious Insidious
Peak age of 
onset
Childhood or 
adulthood
Adulthood Ages 18–24
Usual body 
habitus
Normal Overweight Underweight, normal, or 
sometimes overweight (due to 
CF therapy success)
Likely 
pathophysiology
β-cell dysfunction & 
destruction, primarily 
autoimmune with 
genetic & possible 
environmental causes
Peripheral insulin 
resistance & 
subsequent β-cell 
stress
β-cell destruction due to 
inspissated pancreatic 
secretions, inflammation, and 
replacement with fibrosis & 
amyloid, plus a component of 
β-cell dysfunction
Insulin 
deficiency
Nearly complete Partial and variable Severe but not complete
Insulin 
resistance
Variable Severe Variable depending on 
circumstances (e.g. glycemic 
control, pubertal stage, use of 
glucocorticoids, inflammation)
Ketoacidosis risk High Low Low
Pharmacological 
& dietary 
therapy
• Insulin
• Dietary monitoring 
to ensure appropriate 
insulin dosage
• Insulin or oral 
anti-hypoglycemics
• Low-calorie, 
low-carbohydrate, 
low-fat diet
• Insulin
• Continuation of CF-specific 
diet, designed to prevent 
wasting: high-calorie, high-
carbohydrate, high-fat
Complications Microvascular & 
macrovascular disease
Microvascular & 
macrovascular 
disease
• Decline in nutritional status & 
lung function, associated with 
early mortality
• Microvascular disease
Likeliest cause 
of death
Macrovascular disease Macrovascular 
disease
CF pulmonary disease
Table 1. 
Comparison of common etiologies of diabetes. Adapted from Moran et al. [4].
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glucose, and glycated hemoglobin (HbA1c) [4, 60, 61]. In clinically-stable outpa-
tients with CF, diagnostic criteria are identical to those used for other etiologies 
of diabetes mellitus [4], and are shown in Table 2. Recently, continuous glucose 
monitoring (CGM) has also been used to investigate glucose abnormalities in CF 
patients. This method is not yet widely recommended for diagnosis of diabetes, but 
it is often used to monitor glycemic control or assist insulin dosage [62]. Moreover, 
CGM often detects even earlier CF-related glucose abnormalities than OGTT, in the 
form of intermittent postprandial glucose excursions [63].
This chapter compiles research on use of each glucose measurement method in 
CF patients, with special focus on pre-diabetic patients. The benefits and limita-
tions of each method will be explored to help ascertain when their usage might be 
appropriate. In the process, we will examine correlations between early glucose 
abnormalities and clinical decline. Finally, we will review preliminary evidence of 
improved long-term outcomes with insulin treatment of early glucose abnormali-
ties, supporting their detection and management in routine practice.
Glucose 
measurement 
method
Diagnostic criteria
Normal ranges Pre-diabetic ranges Diabetic ranges
Clinical status Classical symptoms of hyperglycemia, including polyuria, polydipsia, and 
hyperglycemic crisis, may assist diagnosis of diabetes when combined with other 
positive diagnostic tests. Some CF-specific definitions also consider unexplained 
decline in lung function & nutritional status to be classical symptoms.
HbA1c ≤5.6% (38 mmol/
mol)
5.7–6.4% (39–46 mmol/mol) ≥6.5% (48 mmol/mol)
Random blood 
glucose
— — ≥11.1 mmol/L (200 
mg/dL)
Fasting plasma 
glucose
<5.6 mmol/L 
(100 mg/dL)
IFG: ≥5.6 mmol/L (100 mg/
dL), <7.0 mmol/L (126 mg/dL)
≥7.0 mmol/L (126 mg/
dL)
2-h OGTT 0 min: <5.6 mmol/L 
(100 mg/dL)
2 h: <7.8 mmol/L 
(140 mg/dL)
All categories constitute AGT
IFG:
0 min: ≥5.6 mmol/L (100 mg/
dL), <7.0 mmol/L (126 mg/dL)
2 h: N/A
INDET:
0 min: <7.0 mmol/L (126 mg/
dL)
OGTT midpoints: ≥11.1 mmol/L 
(200 mg/dL)
2 h: <7.8 mmol/L (140 mg/dL)
IGT:
0 min: <7.0 mmol/L (126 mg/
dL)
2 h: ≥7.8 mmol/L (140 mg/dL), 
<11.1 mmol/L (200 mg/dL)
0 min: ≥7.0 mmol/L
(126 mg/dL)
AND/OR
2 h: ≥11.1 mmol/L 
(200 mg/dL)
CGM Usually 
<7.8 mmol/L  
(140 mg/dL)
Elevations ≥7.8 mmol/L (140 mg/dL) are referred to as 
glucose excursions, but there are no standardized criteria 
correlating them with AGT or diabetes.
HbA1c = glycated hemoglobin. OGTT = oral glucose tolerance testing. IFG = impaired fasting glucose. 
AGT = abnormal glucose tolerance. INDET = indeterminate glucose tolerance. IGT = impaired glucose tolerance. 
CGM = continuous glucose monitoring.
Table 2. 
Diagnostic criteria of glucose measurement methods commonly used in CF. Diagnosis must occur during 
clinical stability, defined as no pulmonary exacerbations during the past 6 weeks and no current systemic 
glucocorticoids. It is also recommended that any positive fasting plasma glucose, HbA1c, or OGTT is repeated at a 
later date. Non-CGM diagnostic criteria are from the American Diabetes Association [59, 64]. CGM diagnostic 
criteria are from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group [65].
Cystic Fibrosis - Facts, Management and Advances
4
2.  Benefits and limitations of conventional methods used to diagnose 
glucose abnormalities in CF
2.1 Clinical status and/or random blood glucose
The ADA allows diagnosis of CFRD following one random blood glucose mea-
surement ≥11.1 mmol/L, provided that it is combined with polyuria, polydipsia, or 
hyperglycemic crisis [59]. However, symptomatic hyperglycemia or hyperglycemic 
crisis is extremely rare in CFRD [4]. In Lanng et al.’s seminal 5-year prospective 
cohort study of 191 CF patients receiving annual OGTT, only 33% of those diag-
nosed with CFRD had polyuria or polydipsia [54]. Moreover, in a cross-sectional 
study of all 60 patients aged ≥10 years at a Brazilian CF center, age at diagnosis was 
significantly lower for patients diagnosed using OGTT as opposed to clinical criteria 
(13.5 years vs. 22.3 years), implying much earlier detection of disease [66].
Some centers compensate by accepting unexplained decline in lung function or 
nutritional status as classical symptoms of hyperglycemia (see Section 3) [67]. In 
one cross-sectional study of 91 CF patients not known to be diabetic, these modi-
fied clinical criteria detected OGTT-diagnosed CFRD with 58% sensitivity [68], 
which is an improvement over other studies but still suboptimal for a screening test.
2.2 HbA1c
HbA1c, i.e. glycated hemoglobin as a percentage of total hemoglobin, is com-
monly used to monitor glycemic control in diabetes mellitus. It usually reflects aver-
age blood glucose over the life of an erythrocyte (~3 months) [64, 69]. However, 
CF patients with CFRD, INDET or IGT rarely have a significantly-higher HbA1c 
than those with normal glucose tolerance (NGT) [11, 70–73], and even statistically-
significant differences tend to be of <1% magnitude [8, 34, 40, 74, 75]. Godbout 
et al.’s study of 13 CFRD patients also found that HbA1c did not correlate with mean 
plasma glucose, as calculated using fingerprick self-monitoring [76].
Numerous hypotheses have been espoused to explain HbA1c’s relatively poor cor-
relation with glucose tolerance in CF. These include insufficient duration of tran-
sient CF-related post-prandial hyperglycemia, which is often limited to the early 
phase of insulin secretion; alteration of hemoglobin glycation by hypoxia; iron defi-
ciency, which is a common comorbidity of CF; and increased erythrocyte turnover 
in the context of chronic inflammation [1, 4, 5, 76, 77]. This implies that HbA1c may 
vary with degree of inflammation [78], and that trends in HbA1c may be more useful 
for predicting deterioration in glucose tolerance. Supporting this, Lanng et al.’s 
5-year prospective cohort study found significant differences in median HbA1c 
between patients who consistently had NGT (5.2%), patients who varied between 
NGT and IGT (5.3%), patients who developed CFRD during the study (5.8%), and 
patients who entered the study with a diagnosis of CFRD (6.5%) [54].
It has also been hypothesized that poor correlation between mean plasma glu-
cose and HbA1c may be confounded by use of fingerprick tests to measure glucose, 
since these can easily miss CF-related hyperglycaemic peaks due to their relative 
infrequency [76]. In two studies of CF and CFRD patients, mean plasma glucose 
was estimated using 2–7 days of CGM rather than fingerprick self-monitoring, and 
strongly correlated with HbA1c (r = 0.86–0.89) [75, 79].
These findings have regenerated interest in potentially using HbA1c to screen for 
CF-related glucose abnormalities, especially because it is much more convenient 
than OGTT. However, computing HbA1c thresholds suitable for CFRD screening 
has proved challenging. Some studies do report almost 100% sensitivity for OGTT-
defined CFRD using HbA1c thresholds of 6.0–7.5% [40, 80–82], but all have small 
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sample sizes, and most either did not calculate sensitivity to CF-related AGT [81] or 
report low values, ~20–50% [80, 82]. Therefore, HbA1c may not detect CFRD and its 
complications until late. Moreover, most evidence suggests that the diagnostic thresh-
old for CFRD, HbA1c ≥6.5%, has poor sensitivity compared to OGTT [54, 83–85].
Lowering the diagnostic threshold for HbA1c abnormalities does increase 
sensitivity to both CFRD and AGT, but the thresholds required to achieve sufficient 
sensitivity for screening generally have unacceptably low specificity [60]. There is 
also wide variation in the sensitivities and specificities reported by different studies 
using the same HbA1c threshold; this may be due to differences in type of HbA1c 
assay [74, 86] and timing of the studies relative to the institution’s routine OGTT 
screening [87]. Yung et al., conducting a cross-sectional study of 91 CF patients 
not known to be diabetic, but also not previously routinely screened, found that 
HbA1c ≥6.1% had 83% sensitivity for OGTT-diagnosed CFRD [68]. However, more 
recent studies with similar designs report only 30–50% sensitivity [39, 82, 88, 89].
Given this uncertainty, the current advice from the ADA is that HbA1c should not 
be used to screen for CF-related glucose abnormalities [59]. HbA1c is still recom-
mended for monitoring glycemic control in CFRD, although normal results must 
be interpreted with caution [4, 78]. It has also been suggested that HbA1c might be 
a useful adjunct to OGTT in screening, as its results may fluctuate less and hence, 
may more accurately predict long-term risk of glucose abnormalities. In a recent 
6-year retrospective cohort study of 50 NGT adults with CF followed up with 
annual OGTT, HbA1c ≥5.6% had OR 3.49 for development of IGT or CFRD [90].
2.3 Fasting glucose
In 2003, the ADA briefly sanctioned fasting plasma glucose as an alternative to 
OGTT in CFRD screening, because there were insufficient data supporting insulin 
therapy for CFRD without fasting hyperglycemia [91]. However, subsequent studies 
have demonstrated similar insulin-induced clinical improvements in patients with 
and without fasting hyperglycemia [16, 92], and treatment of CFRD without fast-
ing hyperglycemia is now standard practice [4]. Only 16–25% of patients diagnosed 
with CFRD on OGTT have fasting hyperglycemia [8, 54, 68, 81].
Use of fasting glucose to detect pre-diabetic stages on the glucose tolerance spec-
trum remains somewhat contentious in CF. Most studies report that fasting plasma 
glucose does not significantly differ between CF patients with NGT, INDET or IGT 
[39, 72, 93]. The ADA does use fasting glucose to define one pre-diabetic glucose tol-
erance category, IFG (5.6–6.9 mmol/L), and suggested in 2003 that screening OGTTs 
could be limited to IFG patients [94]. A prospective cohort study of 1128 CF patients 
aged 10–64 found that this approach would reduce number of OGTTs by 67%, but 
miss 17.8% of CFRD and IGT [94]. In a cross-sectional analysis of 73 children with 
CF, IFG had 100% sensitivity for CFRD, but only 25% sensitivity for IGT [11].
Finally, like HbA1c, there is debate regarding the utility of IFG as an adjunctive 
test for predicting long-term risk of CFRD. Frohnert et al. found no significant rela-
tionship [95], but Schmid et al. found that IFG generated OR 2.72 for CFRD [96].
2.4 Oral glucose tolerance testing
As discussed above, other conventional diagnostic tests have <100% sensitivity for 
CFRD compared to OGTT. Therefore, OGTT remains the recommended screening 
test in CF. It is also the only test with standardized definitions of multiple pre-diabetic 
glucose abnormalities, all demonstrated to predict development of CFRD [96].
Nevertheless, there are several issues with the 2-h OGTT. It may be more incon-
venient and resource-intensive than other glucose measurement methods, which is 
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of particular concern in CF because patients and clinics already face a high treatment 
burden from other aspects of CF care [97]. It also requires patient co-operation, 
which can be difficult when assessing children [93]. Patients are expected to con-
sume at least 150 g (600 kcal) of carbohydrates for 3 days before an OGTT, then 
fast for 8 h overnight and be tested early the next morning [59]. They must drink a 
solution containing a 1.75 g/kg glucose load, preferably within 5 min, then lie or sit 
quietly for 2 h [64]. In a standard OGTT, venous blood is sampled twice: immedi-
ately before ingestion of the load, and at 120 min (BG120). Many CF centers also take 
hourly or 30-minutely samples to detect post-prandial hyperglycemia that resolves 
before 2 h [59]. As described earlier, these transient post-prandial glucose excursions 
are very common in CF, due to selective impairment of early insulin secretion. Our 
group previously performed OGTT with 30-minutely sampling in 33 children with 
CF aged 10–19, and found that peak venous insulin concentration was delayed until 
90–120 min, producing an early venous glucose peak at 60–90 min [9] (Figure 1).
The inconvenience of OGTT may contribute to poor patient uptake of CFRD 
screening [98–100]. In 2018, the Cystic Fibrosis Foundation Patient Registry 
reported that the average CF center was screening just 61.3% of adolescents and 
32.8% of adults [100]. Rates of utilization of other glucose measurement methods, 
such as HbA1c and fasting glucose, were much higher (92.3% for adolescents and 
89.6% for adults), suggesting that the main barrier to screening is the OGTT itself 
[100]. Suggested solutions include shortening the OGTT to 60 or 90 min [83] or 
replacing it with the 50-g non-fasting 1-h glucose challenge test [89, 101], which is 
currently used to screen for gestational diabetes mellitus in healthy women [101]. 
These modified OGTT protocols are not standard recommended practice [4].
There are also other issues with the OGTT that likely cannot be resolved by 
simply shortening it. Its diagnostic thresholds are not specific to CF and may be 
insensitive to CF-related clinical decline (see Section 3). OGTT results also fre-
quently fluctuate in CF, with a large multicenter prospective cohort study finding 
a variability coefficient 1.5–1.8 times higher than in the general population [55]. 
Similarly, in two 4–5 year prospective cohort studies, 18–58% of AGT patients dem-
onstrated overall improvement in glucose tolerance category, while only 14–22% 
demonstrated deterioration [19, 54].
Finally, even with venous sampling at additional timepoints, the peak blood 
glucose measurements recorded during OGTT may poorly reflect peak blood glucose 
achieved by CF patients in daily life [4, 60, 61]. After all, the OGTT’s 1.75 g/kg 
load contains less glucose than most CF patients’ everyday meals [61, 98]. This has 
prompted research into CF-related glucose abnormalities using CGM, a technology 
that can screen for glucose excursions over a longer interval of everyday life and high 
calorie CF diet.
Figure 1. 
Venous blood glucose (□) and insulin ( ▓ ) in 30-minutely samples over a 2-h oral glucose tolerance test, as 
measured in 33 children with CF aged 10–19. Boxes indicate interquartile range, horizontal lines indicate 
median, whiskers indicate 5th and 95th percentiles. Figure taken from Hameed et al. [9].
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2.5 Continuous glucose monitoring
Most CGM systems consist of two parts: a sterile sensor, worn subcutaneously 
for up to 14 days, and a transmitter attached to the sensor that measures interstitial 
fluid glucose every 30 s, recording an average every 5 min [97] (Figure 2). Some 
systems do not require a separate sensor, instead measuring interstitial fluid glucose 
via an electrical current applied across intact skin, but issues have been reported 
with skin reactions and inaccuracy [102]. Interstitial fluid glucose reflects capillary 
glucose with a 4–20 min delay [103].
CGM has been validated against OGTT in children with CF of all glucose 
tolerance categories [104] and non-diabetic adolescents and adults with CF [105]. 
A subsequent study of this latter group found that they differed significantly from 
healthy controls in mean CGM glucose (+14.1%) and presence of CGM peaks 
≥11.1 mmol/L (+33%), but not in the conventional diagnostic measures of fast-
ing glucose, BG120, and HbA1c [106]. Moreover, 70% of CF patients undertaking 
simultaneous CGM and OGTT had their CGM peak outside OGTT [106]. This was 
the beginning of a substantial body of evidence demonstrating the superior sensi-
tivity of CGM to CF-related glucose excursions above OGTT diagnostic thresholds, 
with numerous studies finding CGM glucose peaks ≥7.8 or 11.1 mmol/L in 71–93% 
of patients classified as NGT on recent OGTT [14, 31, 85, 98, 107, 108]. In a 5-year 
prospective cohort study of 21 adults with CF, 83% had their CGM peak and BG120 
fall in different diagnostic categories, and for 93% the CGM-identified category was 
worse. Again, this suggests the superior sensitivity of CGM over OGTT [98].
Most of this evidence, particularly in children, is limited by small sample sizes 
[14, 85, 98, 107, 108] and lack of non-CF controls [14, 85, 98, 108]. However, it is 
logical that the increased duration and frequency of glucose monitoring facilitated 
by CGM, and the opportunity to incorporate the patient’s usual diet and physical 
activity, facilitates more sensitive detection of glucose excursions [109]. CGM 
is also generally easier and better tolerated than OGTT [78]. While sensors and 
transmitters are expensive, and staff do require training on their usage, they have 
become more user-friendly, smaller and cheaper over time [73, 110]. The newest 
devices can be inserted rapidly during a clinic appointment, do not require calibra-
tion against fingerpricks, and can be removed by patients or carers without medical 
supervision [97].
CGM does have one major disadvantage compared to OGTT. The clinical 
significance of the mild glucose excursions that it detects are still being determined; 
consequently, there is no standardized system for recognizing and describing clini-
cally relevant CGM findings, and no universally accepted threshold for initiation 
Figure 2. 
Continuous glucose monitor sensor, before and after attachment of the transmitter. ‘CGM set’ and ‘Continuous 
Glucose Monitor’ by Sara Bassett are licensed under CC BY-NC-SA 2.0.
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of treatment [97]. Common variables computed by CGM software include aver-
age sensor glucose, maximum glucose, area under the curve of glucose per day 
(AUCglucose/day), percentage time spent above thresholds (e.g. 7.8 or 11.1 mmol/L), 
number of excursions ≥11.1 mmol/L, and measures of glycemic variability, such as 
standard deviation of average sensor glucose [103]. All these parameters have been 
correlated with HbA1c in CF patients [75], and many have been correlated with 
clinical outcomes. However, these studies report heterogeneous findings and rarely 
include substantial prospective follow-up (see Section 3) [84].
Given all these factors, CGM is not yet widely recommended for CFRD diagnosis 
or screening [4]. However, it is used in some centers for diagnosis and screening, 
follow-up of borderline diagnostic tests, and investigation of patients who cannot 
or refuse to undergo OGTT [31, 111, 112]. Like HbA1c, it may also be useful as an 
adjunctive test for predicting long-term risk of CF-related glucose abnormalities. In 
a prospective cohort study of 17 children with CF, all those who had glucose excur-
sions ≥11.1 mmol/L on CGM developed either CFRD or IGT with INDET over a 
period of 2.5 years, irrespective of their glucose tolerance at baseline [107].
3.  Clinical significance of early glucose abnormalities in CF, as detected 
using various glucose measurement techniques
3.1  Defining clinically significant sequelae of CFRD: the importance of lung 
function & nutritional status
CFRD is well-understood to have a differing profile of sequelae as compared 
to T1D or T2D. Macrovascular disease is uncommon outside of case reports  
[1, 4, 5, 113], and although screening for microvascular disease should be 
routinely undertaken [59], microvascular complications are uncommon until at 
least 5–10 years of CFRD with fasting hyperglycemia [57, 114, 115]. Therefore 
they are substantially predated by declines in lung function [6–21, 116–118] and 
nutritional status [7, 9–12, 14, 117], both of which are significant predictors 
of early mortality in CF [10, 11, 16, 18, 25, 56, 119]. Four large cohort studies 
also report higher annual frequency in diabetic vs. non-diabetic CF patients of 
pulmonary exacerbations requiring intravenous antibiotics or hospitalization 
[10, 21, 39, 120], and it was recently demonstrated that diabetic CF patients have 
reduced recovery of baseline forced expiratory volume in 1 sec as a percentage of 
predicted (FEV1%) following pulmonary exacerbations [116].
A causative relationship between CFRD, impaired lung function, and poor 
nutritional status is implied by the clinical improvements seen following insulin 
therapy [13, 92, 120–122], and is also biologically plausible on several accounts. 
Insulin is a powerfully anabolic hormone, therefore insulin deficiency combined 
with CF’s increased metabolic requirements promotes catabolism with nutritional 
decline [9, 93, 123, 124]. Regarding lung function and pulmonary exacerbations, 
hyperglycemia is known to promote respiratory tract infections (RTIs) both 
systemically, via pro-inflammatory and immunosuppressive effects [125, 126], 
and locally, via glucose leakage into airway secretions, which could promote 
pathogen growth [125, 127–130]. Several cohort studies report higher prevalence 
in diabetic vs. non-diabetic CF patients of certain RTIs, including Pseudomonas 
aeruginosa [10, 19, 117, 131], Staphylococcus aureus [132, 133], and Burkholderia 
cepacia [10, 117, 132].
Finally, hyperglycemia can also impair lung function through non-infective 
pathways. It has been associated with restrictive lung disease in T1D and T2D (via 
non-enzymatic glycation of collagen and elastin) [134], and with inflammatory and 
proteolytic lung destruction in CFRD [135–137]. Lung proteolysis may be exacerbated 
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by protein catabolism [19, 122], which can furthermore weaken respiratory muscles 
[138, 139] and impair immunoprotein synthesis during RTIs [61]. This may explain 
why lung function in CF also correlates with nutritional status [6, 7, 140–142].
3.2 Decline in clinical status prior to diagnosis of CFRD
Numerous cohort and case-control studies examining the 1–5 years before CFRD 
diagnosis report decline in lung function [19, 35, 38, 92, 143–146] and nutritional 
status [19, 35, 38, 92, 143, 144] in pre-diabetic patients, or significantly reduced 
values compared to non-diabetic CF controls [12, 17]. This suggests that pre-
diabetic glucose abnormalities are clinically significant. Two case-control studies 
focusing specifically on pediatric populations also report that pre-diabetic children 
with CF have significantly lower height and weight velocities than non-diabetic CF 
controls [145, 146], with one study demonstrating differences up to 11 years before 
CFRD diagnosis [146]. These differing velocities produce steadily-widening gaps 
in height-for-age and weight-for-age, reaching statistically-significant sizes after 
CFRD diagnosis, usually around ages 15–19 [18, 146]. Importantly, this grow-
ing disparity seems to occur even if aggressive insulin therapy is commenced at 
diagnosis [144], and although it may narrow with prolonged therapy, it may not 
fully correct [18, 144, 147]. Therefore, optimizing clinical outcomes in CFRD may 
require treatment of pre-diabetic abnormalities, highlighting the importance of 
glucose measurement systems that can sensitively predict clinical decline.
3.3 Clinically significant pre-diabetic markers detectable using OGTT
Traditional OGTT diagnostic thresholds are not specific to CF – in fact, they 
were originally designed to predict T2D-associated microvascular disease in Pima 
Native Americans [148]. This may explain their apparent insensitivity to CF clinical 
outcomes. A few studies do report poorer lung function or nutritional status in IGT 
vs. NGT CF patients [37, 72], and several more identify IGT as a significant risk fac-
tor for substantial decline in FEV1% over 4–5 years [19, 149]. However, most studies 
attempting to correlate IGT with contemporary lung function and nutritional status 
find no significant relationship [19, 33, 34, 39, 53, 70–73, 150–152].
A more successful non-conventional OGTT parameter is the additional glucose 
tolerance category of INDET, defined as blood glucose ≥11.1 mmol/L at an OGTT 
midpoint – most commonly 60 min (BG60) – as opposed to 0 or 120 min [4]. BG60 
has been shown to inversely correlate with BMI in children with CF, and correlates 
with FEV1% and forced vital capacity as a percentage of predicted (FVC%) in 
both children [7] and adults [150]. In a subsequent study, INDET patients had 
mean FEV1% comparable to CFRD patients, representing a significant reduction 
compared to NGT and IGT patients [71]. INDET has also been confirmed to predict 
development of CFRD (OR 2.81 over ~3.5 years) [93, 96].
Other OGTT parameters shown to predict FEV1% in non-diabetic CF patients 
include higher peak glucose (BGmax) [9, 33, 72, 153], higher AUCglucose [124, 153], 
and reduced insulin secretion [34, 35, 72, 124]. Finally, a few studies have correlated 
FEV1% with trajectories of deterioration in glucose tolerance [41, 154]. One pro-
spective cohort study recruited 152 non-diabetic CF patients, and stratified them 
according to whether their glucose tolerance on OGTT improved, deteriorated or 
remained stable over 2 years [41]. While all patients experienced a decline in FEV1%, 
the extent of decline only reached statistical significance in patients of stable or 
deteriorating glucose tolerance, and those of deteriorating glucose tolerance also had 
a much larger drop than those of stable glucose tolerance (−6.1% vs. −1.6%) [41].
It is rarer for studies to report correlations between OGTT parameters and 
nutritional status [33–35, 41, 71, 72, 154], possibly because intensive dietician 
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management of CF mitigates nutritional decline [133, 154]. Nevertheless, one 
seminal prospective cohort study inversely correlated age-adjusted height and 
BMI with AUCglucose [8], and a recent cross-sectional study found that lower-than-
median insulin secretion at 60 min is independently associated with worse BMI 
[150]. In children, BMI (calculated as weight in kg divided by the square of height in 
meters) may be a less sensitive measure of nutritional status than weight-for-age, as 
poor linear growth may mask decline [146]. Nevertheless, Wooldridge et al. report a 
direct correlation between AUCinsulin and BMI z-score in 146 NGT children with CF 
aged 5–20 [123], and our group has found that AUCglucose inversely correlates with 
age-adjusted weight, height and BMI in children aged ≤10 years [153]. Furthermore, 
in an earlier cohort study of 33 children aged 10–19, we found that higher BGmax 
was associated with decline in weight z-score, FEV1% and FVC% over the past 12 
months, and BGmax ≥8.2 mmol/L had 87% sensitivity and 70% specificity for a 
clinically significant decline in weight z-score [9]. By contrast, BG120 was no better 
than chance at detecting decline in weight z-score, and the conventional diagnostic 
threshold of 11.1 mmol/L had only 10% sensitivity [9]. These findings led us to 
propose an alternative system for classifying CF-related glucose abnormalities on 
OGTT, the Cystic Fibrosis Insulin Deficiency (CFID) stages (Table 3) [9].
3.4 Clinically significant pre-diabetic markers detectable using CGM
Six main studies have explored the clinical significance of CGM-based measures 
of CF-related early glucose abnormalities [9, 98, 111, 152, 155, 156]. Their results are 
compelling but heterogeneous. Taylor-Cousar et al. conducted a 5-year prospective 
cohort study of 17 originally non-diabetic CF patients, 7 of whom developed CFRD 
during observation [98]. In this subgroup, there was significant inverse correlation 
between peak glucose and BMI, and a trend towards correlation with FEV1% [98]. 
Leclercq et al. also examined peak glucose, stratifying 38 NGT CF patients accord-
ing to whether they had any peaks ≥11.1 mmol/L during 72-h CGM [155]. In the 
‘yes’ group, there was significantly lower FEV1% and FVC%, and increased risk of 
colonization with P. aeruginosa [155].
In the aforementioned study undertaken by our research group in 33 children 
with CF aged 10–19, we also showed that percentage time ≥7.8 mmol/L on CGM 
predicted 12-month rate of decline in weight z-score, FVC%, and FEV1%. Similarly, 
on receiver operator characteristic (ROC) analysis, ≥4.5% time at ≥7.8 mmol/L on 
CGM was a sensitive and specific predictor of clinically significant decline in weight 
z-score and FVC% [9]. Frost et al. subsequently used these parameters to interpret 
the CGM results of 59 adults being investigated for CF-related glucose abnormali-
ties [112]. They found that percentage time ≥7.8 mmol/L on CGM correlated with 
baseline FEV1% and 12-month rate of decline [112].
In Chan et al.’s study of 88 children with CF aged 10–18, 12-month decline in 
FEV1% and FVC% was predicted by multiple other CGM parameters: peak glucose, 
number of daily glucose excursions >11.1 mmol/L, mean amplitude of glycemic 
Diagnostic category o-min OGTT glucose Max OGTT glucose 2-h OGTT glucose
CFID1 <7.0 mmol/L ≥8.2 mmol/L <11.1 mmol/L
CFID2 <7.0 mmol/L ≥11.1 mmol/L <11.1 mmol/L
CFID3 <7.0 mmol/L N/A ≥11.1 mmol/L
CFID4 ≥7.0 mmol/L N/A N/A
Table 3. 
Cystic fibrosis insulin deficiency (CFID) classification system of CF-related glucose abnormalities, as proposed 
by Hameed et al. [9].
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excursions, and standard deviation [152]. Brugha et al. investigated another gly-
cemic variability measure, glucose interquartile ranges, in a 7-year retrospective 
cohort study [111]. On ROC analysis, ranges >1.95 mmol/L predicted CFRD with 
60% sensitivity and 98% specificity, but did not correlate with BMI or FEV1% [111].
Finally, our group recently conducted a cross-sectional study of 18 children 
with CF aged ≤5 years [156]. Even in this very young group, history of P. aeruginosa 
was predicted by mean glucose and percentage time at ≥7.8 mmol/L, and levels of 
inflammatory markers in bronchoalveolar lavage fluid were predicted by peak glu-
cose, mean glucose, percentage time at ≥7.8 mmol/L, and standard deviation [156].
3.5  Clinically significant pre-diabetic markers detectable using other glucose 
measurement techniques
3.5.1 HbA1c and alternative glycated proteins
Three studies report a weak inverse correlation between HbA1c and lung func-
tion in non-diabetic CF patients (r = −0.25–0.3) [72, 73, 88], and one of these also 
found a direct correlation with number of infective pulmonary exacerbations per 
year [73]. In two more studies, HbA1c ≥ 5.5–5.8% predicted poorer FVC% [74] or 
FEV1% [82]. Therefore HbA1c, despite its insensitivity to CF-related glucose abnor-
malities, may be a useful harbinger of clinical decline when elevated.
Several studies have also investigated fructosamine, glycated albumin, and 
1,5-anhydroglucitol as alternatives to HbA1c in CF. These biomarkers are not depen-
dent on the lifespan of erythrocytes, and have been shown to correlate with mean 
plasma glucose in CF as estimated using CGM [75]. However, evidence of their 
ability to predict glucose abnormalities and clinical decline in CF is currently mixed 
[11, 74, 157]. In one study, fractional serum fructosamine (FSF) ≥3.70 μmol/g 
predicted IGT and CFRD with 100% sensitivity and 67% specificity, and patients 
with elevated FSF also had significantly lower median FEV1% (47% vs. 90%) [157].
3.5.2 Fasting glucose
Early evidence suggests that fasting glucose, including IFG, does not correlate 
with clinical status in CF [53, 95]. In one case-control study, IFG actually predicted 
better lung function than normal fasting glucose in some patient subgroups, 
particularly children with simultaneous IGT [95]. It was hypothesized that IFG may 
represent a physiological adaptation to CF, with hepatic glucose production upregu-
lated to meet increased baseline metabolic requirements [95].
4.  Detection protocols for early glucose abnormalities and CFRD at the 
Sydney Children’s Hospital, Randwick
Our institute, the Sydney Children’s Hospital, provides one example of inte-
grating multiple glucose measurement methods into routine practice. Children 
with CF are screened annually for glucose abnormalities from age 10, using OGTT 
with 30-minutely sampling. CGM is used to follow up borderline OGTTs, or to 
investigate children with clinically-suspected glucose abnormalities who have 
normal OGTTs or are unable to undergo OGTT. CGM excursions ≥11.1 mmol/L 
over 72 h of monitoring are considered severe abnormalities that warrant further 
investigation for possible insulin therapy. Moreover, some pre-diabetic children 
on OGTT are randomized to insulin therapy via the CF-IDEA trial (ClinicalTrials.
gov Identifier NCT01100892, see Section 5).
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5. Management of early glucose abnormalities in CF
Ultimately, the most clinically relevant measures of CF-related early glucose 
abnormalities are those that alter patient management. Therefore the long-term 
effects of actively treating early abnormalities is an important research question. 
Most studies have focused on insulin therapy, as insulin is currently the only 
recommended pharmacotherapy for CFRD (in part because of its anabolic effects) 
[59]. Emerging research has also explored oral anti-hypoglycemics [158], incretin 
modifiers [159], and CFTR modulators [160, 161].
It is already known that earlier diagnosis and treatment of CFRD, via OGTT 
screening programs, improves life expectancy and resolves historical sex differ-
ences in clinical outcomes (females with CFRD previously did worse than males) 
[16, 24]. Seven studies were identified trialing insulin therapy for CF patients who 
were pre-diabetic on OGTT [92, 122, 143, 162–164]. Five report statistically-signif-
icant improvements in lung function [122, 163, 165], nutritional status [122, 143, 
164, 165], or rate of decline in either variable [163, 164], either intra-individually 
or relative to untreated controls. Moreover, five out of six studies assessing toler-
ability found no significantly-increased incidence of symptomatic hypoglycemia 
[92, 122, 143, 162, 164, 165]. Finally, one additional study has assessed the effi-
cacy of insulin therapy initiated based on CGM, via retrospective analysis of all 
non-diabetic adults at a British CF center who had a CGM ordered between 2013 
and 2016 [112]. Insulin was initiated if patients spent >4.5% time at >7.8 mmol/L 
on CGM, and if they recorded no clear triggers for these glucose excursions in a 
contemporary food diary. Patients treated with insulin demonstrated statistically-
significant improvements in FEV1% and weight within 3 months of treatment, and 
maintained an improvement in weight and annual rate of lung function decline at 
12 months [112].
All this suggests that treatment of CF-related AGT may be beneficial. 
However, results are difficult to generalize, due to heterogeneity in studies’ 
inclusions criteria, types of controls, and insulin regimens [166]. Studies are also 
limited by small sample sizes [92, 112, 122, 143, 162–165], short durations [92, 
112, 122, 143, 162, 165], and mixed analysis of pre-diabetic and diabetic patients 
[92, 122], highlighting the need for large long-term randomized control trials. 
One such trial, CF-IDEA (ClinicalTrials.gov Identifier NCT01100892), is near-
ing completion. To date, CF-IDEA has recruited 86 participants aged ≥5 years 
at 5 participating sites, all non-diabetic on OGTT with BGmax 8.2 mmol/L to 
<11.1 mmol/L (CFID1) or ≥ 11.1 mmol/L (CFID2). Participants are randomized 
to observation only or to a once-daily insulin detemir (Levemir) for 12 months, 
with starting dose 0.1 units/kg/day, blood glucose self-monitoring intensively 
for 10 days and twice daily thereafter, and a blood glucose target range of 
4–8 mmol/L. The main outcome factors are change in weight SDS, change in lung 
function, and frequency of hospitalization.
6. Conclusions
As patients with CF live longer, CFRD becomes an increasingly prevalent 
serious co-morbidity, associated with significant decline in lung function and 
nutritional status. Evidence suggests that this decline may begin years earlier, in 
the pre-diabetic phase. Currently, OGTT is the most sensitive licensed diagnostic 
tool for identifying pre-diabetic CF-related glucose abnormalities, but its utility 
is limited by inconvenience, high variability of results, and insensitivity of tradi-
tional diagnostic categories to CF-related glucose excursions and clinical decline. 
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